AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00236184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Study NCT00236184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Study NCT01085812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
Study NCT01085812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be given orally, in capsule form, once daily.
Study NCT04150185 — intervention group
Intervention type: PROCEDURE
Intervention: Donor hepatectomy
Study NCT00469456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine 20mg (10mg twice daily) oral administration for 12 weeks
Study NCT00469456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo oral administration twice daily for 12 weeks
Study NCT02541045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metadoxine
Description: metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
Study NCT02541045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets: 1 Tablet by mouth twice in day during 6 months
Study NCT01035047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision unit care, coupled with cardiac MRI
Description: After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
Study NCT02316288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Acceptance Therapy
Description: Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
Study NCT02316288 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
Study NCT02785731 — intervention group
Intervention type: PROCEDURE
Intervention: Pelvic imaging
Description: Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
Study NCT02785731 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
Study NCT02785731 — intervention group
Intervention type: PROCEDURE
Intervention: laparotomy or laparoscopy
Description: A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
Study NCT01168336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine standard formulation
Description: betahistine 24 mg tablets
Study NCT01168336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine Extended Release formulation
Description: betahistine 32 mg tablets
Study NCT01168336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT01973062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01973062 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study NCT00135577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan
Study NCT00135577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02720861 — intervention group
Intervention type: GENETIC
Intervention: DNA sequencing
Description: withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene
Study NCT00135577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05410119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week Resilience Group Psychotherapy
Description: Resilience Group Psychotherapy was intervened by a psychotherapy developed by the researchers. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
Study NCT05410119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care means treating as usual, such as regular home visit.
Study NCT01127321 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
Study NCT01127321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-570 0.03 MG
Description: A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
Study NCT01127321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-570 0.1 MG
Description: A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
Study NCT01127321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-570 0.3 MG
Description: A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
Study NCT01127321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-570 1 MG
Description: A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
Study NCT00085111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT02171130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: 3 mg nasal glucagon powder
Study NCT01895049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus
Study NCT01895049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus
Study NCT03202485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toric Implantable Collamer Lens
Description: uses Toric Implantable Collamer Lens implantation to correct the high myopic astigmatism.
Study NCT03202485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICL + Astigmatic keratotomy
Description: uses Implantable Collamer Lens implantation combined with Astigmatic keratotomy to correct the high myopic astigmatism
Study NCT05098691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum marker levels
Description: two groups comparisons
Study NCT03535805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind My Mind (MMM)
Description: Mind My Mind (MMM) is a new transdiagnostic and modular cognitive and behavioural therapy (CBT) program comprising evidence-based interventions for children and adolescents with anxiety, depression or disruptive behavior.~MMM manual consists of evidence-based CBT methods that are organized into modules. The intervention is tailored to the individual child by the dosing and the sequencing of the modules. Trauma-focused CBT is available. Parents are engaged in child's therapy and support the child in doing the homework. Parent management training is offered for behavioral disturbances. The educational psychologists deliver the therapy after one-week training in the manual, followed by weekly supervision. The treatment fidelity is monitored by video observation of therapy sessions (>20%).~The MMM training program consists of 9-13 sessions plus one booster, all completed within 17 weeks.
Study NCT02290145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF group
Description: The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day
Study NCT02290145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery group
Description: The patients in the control group received the radical surgery and post-operative radiotherapy.
Study NCT02290145 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery group
Description: The patients in the control group received the radical surgery and post-operative radiotherapy.
Study NCT02290145 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
Study NCT03535805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: The parents in the TAU group are offered two sessions (week 2 and week 17) to support their attempts to seek help for the child in the municipality. This coordination is provided by psychologists (or other local professionals) who hold records of the currently available treatment options in the municipality. The TAU vary considerably from no intervention to counselling, talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. Some children are offered CBT interventions, but access to manualized treatment is generally very limited.
Study NCT01068288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic or open appendectomy
Study NCT01068288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expectant Management
Description: A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.~For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy.
Study NCT00069381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment
Study NCT03413215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive
Description: Patients are provided with a BP machine, glucometer and test strips, and instructed how to use either a written or smartphone logbook, photograph their meals and use smartphone apps to measure daily activity. DNEs will contact patients in between visits to reinforce adherence and self-monitoring.~MSWs will conduct at least 6 face-to-face sessions, at 3 weeks then less frequently, on essential self-care behaviours in people with diabetes: healthy eating; being physically active; monitoring of blood sugar; compliance with medications; problem-solving; healthy coping skills; and risk-reduction behaviour.~Renal pharmacists will see patients at 2-4 week intervals for 3 months after the first clinic visit, and subsequently every 3-6 months. They will review patient's compliance, laboratory results and home BP, educate patient and titrate antihypertensives to meet BP goal. Physician referrals will be made for severe hypertension or hypotension, or intolerable side effects.
Study NCT02290145 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Post-operative radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
Study NCT00332306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Didanosine, Lamivudine, Efavirenz
Description: Didanosine 250mg patients \<60kg, 400mg patients > 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
Study NCT00332306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine, Lamivudine, Nevirapine
Description: Didanosine 250 mg once daily for patients \< 60kg, 400 mg OD patients > 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
Study NCT04261010 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Global/single cell gene expression profiles obtained from Synovial biopsies
Description: Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.
Study NCT04261010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global/single cell gene expression profiles obtained from Synovial biopsies
Description: Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.
Study NCT01014481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir, lamivudine, efavirenz
Description: initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
Study NCT04644159 — intervention group
Intervention type: OTHER
Intervention: Human biological samples
Description: Blood , saliva, nasopharyngeal mucosa
Study NCT04876976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate, Isobutyl
Description: using cyanoacrylate in the surgical repair of urethro-cutaneous fistula
Study NCT04876976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic surgical repair
Description: classical repair of urethro-cutaneous fistula without the use of cyanoacryalte
Study NCT02742675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given orally
Study NCT02742675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given subcutaneously or as an injection
Study NCT02742675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Given orally
Study NCT02742675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given subcutaneously or as an injection
Study NCT02742675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: Given subcutaneously or as an injection
Study NCT02742675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive Treatment
Description: surgery to remove prostate or radiation therapy to the prostate.
Study NCT04153968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-cryptoxanthin
Description: Phase 1:~2.0mg of \[13C14\]β-cryptoxanthin, 1.0mg of \[13C10\]β-carotene and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil at Time 0.~Phase 2:~1.5mg of \[13C14\]β-cryptoxanthin, 0.75mg of \[13C10\]β-carotene, 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.25mg β-carotene and 0.5mg β-cryptoxanthin from maize are given at Time 0.~Then, 0.75mg of \[13C14\]β-cryptoxanthin, 1.5mg of \[13C10\]β-carotene, and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.5mg β-carotene and 0.25mg β-cryptoxanthin from maize are given on day 21.
Study NCT02907775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ShefStim
Description: Electrode arrays will be worn over the affected arm with stimulation applied over the extensor aspect of the upper arm
Study NCT02907775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrodes
Description: electrodes placed over the radial nerve in radial grove
Study NCT03246919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta
Study NCT03246919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered after delivery of the placenta
Study NCT02768922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aphasia telerehabilitation
Description: Speech and language therapy delivered by speech-language pathologist via computer and telemedicine
Study NCT02768922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard face-to-face aphasia rehabilitation
Description: Speech and language therapy delivered by speech-language pathologist face-to-face (treatment as usual)
Study NCT02768922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard face-to-face aphasia rehabilitation
Description: Speech and language therapy delivered by speech-language pathologist face-to-face (treatment as usual)
Study NCT00590538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium 4-Phenylbutyrate
Description: The standard oral adult dose is 20 g/day (tablets) for 4 days.
Study NCT00590538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genistein (Unconjugated Isoflavones 100)
Description: Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
Study NCT00590538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Genistein (Unconjugated Isoflavones 100)
Description: Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
Study NCT00590538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is given to match the active comparator for four days.
Study NCT02667626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reproductive Health Survivorship Care Plan (SCPR)
Description: The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
Study NCT02667626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Web-based resource lists and text-based study adherence reminders
Study NCT03609957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Traditional, continuous aerobic exercise (cycling) at a moderate intensity
Study NCT03609957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: High-intensity interval exercise consisting of short bursts of exercise interspersed with rest periods
Study NCT02444039 — intervention group
Intervention type: DEVICE
Intervention: SL-D301
Description: Slit Lamp
Study NCT02444039 — intervention group
Intervention type: DEVICE
Intervention: DC-4
Description: Digital Camera Attachment
Study NCT02444039 — intervention group
Intervention type: DEVICE
Intervention: SL-3G
Description: Slit Lamp
Study NCT03726736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined Docetaxel
Description: Anlotinib ( dose base on phase I study, QD PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
Study NCT03726736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
Study NCT02451397 — intervention group
Intervention type: OTHER
Description: This is a cross-sectional study, and we do not assign specific interventions to the subjects of the study.
Study NCT03787199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Andago
Description: The Andago is a body-weight supporting device with which a patient can walk overground
Study NCT03787199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Bodyweight supported treadmill walking
Study NCT04100590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Smoked active cannabis (7% THC) vs. placebo inactive cannabis (0% THC)
Study NCT04100590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Description: Smoked active cannabis (7% THC) vs. placebo inactive cannabis (0% THC)
Study NCT02179476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glyder
Description: The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation in one or two lumbar facet levels